Clinical Trial

Results from XVIVO’s Clinical Trial NIHP2019 for Heart Preservation Presented at ISHLT in Prague

GOTHENBURG, SWEDEN / ACCESSWIRE / April 11, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today, at the 2024 International Society of…

9 months ago

Aptevo Therapeutics Provides Pipeline Update

Breast cancer patient who improved from a progressive disease diagnosis to an over nine-month sustained stable disease diagnosis has now…

9 months ago

Yunu Adds Pediatric Oncologist Dr. Scott Bradfield as Strategic Advisor

Collaboration aims to advance pediatric oncology trial precision with the latest imaging technology.CARY, NC / ACCESSWIRE / April 10, 2024…

9 months ago

BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference

MISSISSAUGA, Ontario, April 10, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will…

9 months ago

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

FREMONT, CA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing…

9 months ago

Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders

Company not implementing a reverse split at this timeTop line results forthcoming for company's phase 3 OnTarget trial of crofelemer…

9 months ago

SRx Health Solutions Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Toronto, Ontario--(Newsfile Corp. - April 9, 2024) - SRx Health Solutions Inc., a leading Canadian healthcare service provider specializing in…

9 months ago

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

BASKING RIDGE, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…

9 months ago

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”

Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension…

9 months ago